If true, therapeutic strategies targeting neuronal ISG15, ISG15-specific E3 ligases, or key EV-associated miRNAs that are disrupted by ISG15 induction may prove invaluable to halting GM atrophy-related clinical progression and to mitigating or reversing cognitive impairment in patients with MS. This evidence concerns the gene ISG15 and Cognitive impairment.